Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Consensus Guidelines for the Management of Plaque Psoriasis ARCHIVES OF DERMATOLOGY Hsu, S., Papp, K. A., Lebwohl, M. G., Bagel, J., Blauvelt, A., Duffin, K. C., Crowley, J., Eichenfield, L. F., Feldman, S. R., Fiorentino, D. F., Gelfand, J. M., Gottlieb, A. B., Jacobsen, C., Kalb, R. E., Kavanaugh, A., Korman, N. J., Krueger, G. G., Michelon, M. A., Morison, W., Ritchlin, C. T., Gold, L. S., Stone, S. P., Strober, B. E., Van Voorhees, A. S., Weiss, S. C., Wanat, K., Bebo, B. F. 2012; 148 (1): 95-102

Abstract

The Canadian Guidelines for the Management of Plaque Psoriasis were reviewed by the entire National Psoriasis Foundation Medical Board and updated to include newly approved agents such as ustekinumab and to reflect practice patterns in the United States, where the excimer laser is approved for psoriasis treatment. Management of psoriasis in special populations is discussed. In the updated guidelines, we include sections on children, pregnant patients or pregnant partners of patients, nursing mothers, the elderly, patients with hepatitis B or C virus infections, human immunodeficiency virus-infected patients, and patients with malignant neoplasms, as well as sections on tumor necrosis factor blockers, elective surgery, and vaccinations.

View details for Web of Science ID 000299653900018

View details for PubMedID 22250239